GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Price-to-Owner-Earnings

Medigen Biotechnology (ROCO:3176) Price-to-Owner-Earnings : (As of May. 31, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Price-to-Owner-Earnings?

As of today (2024-05-31), Medigen Biotechnology's share price is NT$43.10. Medigen Biotechnology does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Medigen Biotechnology's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Medigen Biotechnology was 971.59. The lowest was 20.43. And the median was 625.39.


ROCO:3176's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-31), Medigen Biotechnology's share price is NT$43.10. Medigen Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-3.89. Therefore, Medigen Biotechnology's PE Ratio for today is At Loss.

As of today (2024-05-31), Medigen Biotechnology's share price is NT$43.10. Medigen Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in was NT$-3.81. Therefore, Medigen Biotechnology's PE Ratio without NRI for today is At Loss.

During the past 13 years, Medigen Biotechnology's highest PE Ratio without NRI was 157.89. The lowest was 0.00. And the median was 105.66.


Medigen Biotechnology Price-to-Owner-Earnings Historical Data

The historical data trend for Medigen Biotechnology's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Price-to-Owner-Earnings Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 689.23

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 20.96 689.23 -

Competitive Comparison of Medigen Biotechnology's Price-to-Owner-Earnings

For the Biotechnology subindustry, Medigen Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Price-to-Owner-Earnings falls into.



Medigen Biotechnology Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Medigen Biotechnology's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=43.10/-1.20
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology  (ROCO:3176) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Medigen Biotechnology Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines